Business Context and Reporting Period
Company: Quantum X Labs Inc. (formerly Viewbix Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: The Company operates in three primary areas: digital advertising (Search Platform via Gix Media), enterprise AI (Metagramm), and quantum technology (Quantum Israel). The Company ceased operations in its digital content segment (Cortex) following its sale in November 2025.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 |
|---|---|---|
| Revenues | $646 | $293 |
| Operating Loss | $(1,945) | $(1,395) |
| Net Income (Loss) Attributable to Shareholders | $1,880 | $2,485 |
| Cash and Cash Equivalents (End of Period) | $2,435 | $2,435 |
| Total Debt (Short-term + Long-term) | $1,905 | $1,905 |
| Accumulated Deficit | $(44,167) | $(44,167) |
Note: Net income for the period is primarily driven by a non-recurring gain from the deconsolidation of a subsidiary (see Material Changes).
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased to $646k (6 months 2026) from $899k (6 months 2025). This is attributed to browser technology updates reducing direct model distribution and the cessation of the digital content segment.
- Operating Expenses: General and administrative expenses increased significantly to $1,515k (6 months 2026) from $755k (6 months 2025), driven by professional services post-Nasdaq uplisting and the consolidation of Quantum Israel.
- Acquisition of Quantum Israel: Closed March 4, 2026. The Company acquired 100% of Quantum Israel, a quantum technology hub, for consideration including common stock and pre-funded warrants. This added $14.3M in goodwill and $508k in in-process R&D.
- Deconsolidation Gain: Recognized a gain of $3,831k due to the loss of control of CliniQuantum (a subsidiary of Quantum Israel) in June 2026. This gain turned an operating loss into a net profit for the period.
- Financial Expenses: Net financial expenses dropped to $184k (6 months 2026) from $10,528k (6 months 2025). The prior year figure included significant fair value adjustments on financial instruments that were converted to equity in 2025.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the 12 months following the issuance date due to recurring losses, negative operating cash flows, and an accumulated deficit of $44.2M. The financial statements do not include adjustments that might be necessary if the Company cannot continue.
- Liquidity Strategy: The Company is raising capital through private placements (e.g., $1.4M in March 2026) and warrant exercises. Management is reducing salaries, professional services, and operational overheads.
- Geopolitical Risk: The Company is based in Israel. While customers are primarily in the U.S. and Europe, ongoing regional conflicts (Gaza, Lebanon, Iran) create uncertainty regarding the duration and economic impact on operations.
- Acquisition Integration: Risks exist regarding the ability to realize anticipated benefits from the Quantum Israel and Metagramm acquisitions, including integration challenges and unanticipated costs.
- Debt Obligations: The Company has outstanding bank loans and convertible loans totaling approximately $1.9M. Failure to meet debt obligations or secure additional financing could force a curtailment of operations.
Investor Verification Checklist
- Verify the Sustainability of Net Income: Confirm that the reported net income of $1.88M is non-recurring, driven almost entirely by the $3.83M gain from deconsolidating CliniQuantum, rather than core operational profitability.
- Assess Liquidity Runway: Review the $2.435M cash balance against the $1.905M debt and negative operating cash flow of $1.666M (6 months) to determine the immediate need for further capital raises.
- Review Earn-Out Liabilities: Examine the $994k total earn-out liability (current and non-current) associated with the Metagramm and Quantum Israel acquisitions and the specific milestones required to trigger additional share issuance.
- Monitor Debt Covenants: Verify compliance with financial covenants on the Gix Media bank loans and the status of the June 2024 Facility Agreement, which involves convertible features.
- Check Subsequent Events: Note that subsequent to June 30, 2026, the Company converted $589k of debt into equity and exercised additional warrants, further diluting existing shareholders.